Searched for
GENERICS
Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginallyDr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America ...- GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
- Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruptionDr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda i...
- Jubilant Pharmova eyes $150 million through rupee debt sale, bankers sayJubilant Pharmova plans to raise around Rs 14 billion ($150 million) through a three-year rupee bond offering to fund capital expenditure a...
- Why do diets fail despite your best efforts? How expert nutrition support can helpMost diets fail not because of weak willpower but because generic plans ignore your food, routine and health needs, then leave you alone wh...
- Trump's approval ratings fall to record lows – here's what it means for him and the Republican Party ahead of the midterm elections on Nov. 3Donald Trump's approval ratings have fallen significantly in recent polls ahead of the upcoming midterm elections. According to the New Yor...
- Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancerDr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new...
- Trump approval falls to record low of 31% as midterms near, Reuters/Ipsos poll findsA recent Reuters/Ipsos poll shows Democrats leading Republicans by 12 points in the generic congressional ballot. This significant advantag...
- GLP-1 prices drop at Mochi Health, starting at $60 but what will patients actually pay?Mochi Health has reduced their prices for their GLP-1 weight loss medications. While the membership fees is entirely separate, they have me...
- NATCO Pharma subsidiary launches Carboplatin in US market to address shortagesIndian pharmaceutical company NATCO Pharma annouced the launch of Carboplatin Injection, a generic version of Paraplatin in the US market b...
- Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select playersIndia's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...
- 5 stocks with consistent score improvement and upside potential of up to 29 % in 1 year, according to analystsLook at how the market treated the stock of a large FMCG stock – one the best wealth creators of the past – just because it mentioned the r...
- Long-term investing is about looking beyond narratives, including AI: 5 large-caps with an upside potential of up to 24%As we see a recovery in the market, it is good to be cognizant of the fact that more than the narratives on the street, it is the earnings ...
- Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launchBiocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...
- Biocon clears path for cancer drug launchBiocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...
- Biocon founder Kiran Mazumdar Shaw says India must shift pharma industry from generics to innovation-led growthKiran Mazumdar-Shaw emphasized the importance of building an innovation-driven pharmaceutical industry in India. She highlighted the need f...
- India, America expanding cooperation across sectors: US ambassador Sergio GorKolkata and the United States are strengthening ties across sectors such as defence, IT, and healthcare. Recent military exercises involvin...
- SC asks govt to broaden inflated pricing review beyond oncologyThe Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...
- 'Stay tuned for...': US envoy Sergio Gor on India-US ties after Modi-Trump talksUS Ambassador Sergio Gor emphasized the strengthening collaboration between India and America in defense and healthcare sectors. During an ...
- Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-ShawBiocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push f...
Load More
